# Endoscopic and Microbiological Assessment of the Effect of Carvedilol Combined With Berberine on GOV in Cirrhosis

> **NCT04543643** · PHASE3 · UNKNOWN · sponsor: **Tianjin Second People's Hospital** · enrollment: 288 (estimated)

## Conditions studied

- Cirrhosis Due to Hepatitis B
- Cirrhosis Due to Hepatitis C
- Gastroesophageal Varices

## Interventions

- **DRUG:** Carvedilol
- **DRUG:** Berberine

## Key facts

- **NCT ID:** NCT04543643
- **Lead sponsor:** Tianjin Second People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-11-01
- **Primary completion:** 2023-10-31
- **Final completion:** 2023-10-31
- **Target enrollment:** 288 (ESTIMATED)
- **Last updated:** 2021-10-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04543643

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04543643, "Endoscopic and Microbiological Assessment of the Effect of Carvedilol Combined With Berberine on GOV in Cirrhosis". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT04543643. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*